On November 30, 2023 Guardant Health, a leading precision oncology company, reported the company will present data showing the utility of liquid biopsy tests in the management of breast cancer patients at the San Antonio Breast Cancer Symposium, December 5-9 in San Antonio, Texas (Press release, Guardant Health, NOV 30, 2023, View Source [SID1234638083]). Highlights of the eight poster presentations include the use of blood-based testing to identify actionable biomarkers and predict therapy response in advanced breast cancer, and to detect residual disease and predict recurrence in patients with early-stage breast cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We look forward to sharing new data in San Antonio demonstrating the utility of liquid biopsy in advancing the practice of precision oncology for patients with breast cancer," said Craig Eagle, Guardant Health chief medical officer. "The presentations will show how comprehensive genomic profiling and residual disease detection using blood-based testing provide critical insights to help oncologists develop personalized treatment plans that can improve patient outcomes."

Two studies were selected for spotlight discussions:

The PlasmaMATCH study assessed the feasibility of ctDNA genomic profiling for actionable biomarker detection and therapy selection in patients with advanced breast cancer. This research explores the use of ctDNA at multiple points in time to predict therapy response in patients on targeted therapy, including establishing thresholds that best predict clinical outcomes. Study results show the use of longitudinal sampling and ctDNA assessment may help in understanding, predicting and preparing for clinical outcomes in patients receiving systemic therapy.
In a large feasibility study of over 300 patients with early-stage breast cancer, samples were collected about two years after curative-intent adjuvant chemotherapy and tested with Guardant Reveal, using epigenomic technology to assess for the presence of ctDNA. The study found ctDNA detection after adjuvant therapy was prognostic for distant recurrence, with a median lead time between detection and clinically observed disease recurrence of 7.9 months and high specificity. The study also notes that ctDNA was detected up to 28.6 months prior to clinical recurrence detection.
Guardant Health poster presentations

Guardant360 and GuardantOMNI

The prognostic and predictive impact of circulating tumor DNA (ctDNA) dynamics in patients with metastatic Triple Negative Breast Cancer (TNBC) on olaparib based therapy: Results from Cohort E of the PlasmaMATCH trial (Poster spotlight discussion PS06-04)
Guardant360 CDx

Cell-free tumor DNA analysis in advanced or metastatic breast cancer patients enrolled in the German registry study PRAEGNANT (Poster P04-05-03)
Guardant360

CDK4/6 inhibition is a potential vulnerability in NF1-depleted ER+ breast cancer (Poster GS01-08)
Enhancing Informative Outcomes with Liquid Biopsy in a Real-World Population of Patients with Advanced Breast Cancer: Analysis of the SOLTI-1903 HOPE Study (Poster P04-14-02)
Detection of SPEN mutations in advanced breast cancer by circulating tumor cell-free DNA (Poster P05-14-07)
Guardant Reveal

Analysis of ctDNA for the detection of minimal residual disease (MRD) using a tissue-free, multiomic assay in patients with early-stage breast cancer (Poster spotlight discussion PS06-06)
Guardant INFORM

A bedside-to-bench translational analysis demonstrates that NF1 alterations promote CDK4/6 inhibitor (CDK4/6i) resistance in hormone receptor-positive (HR+) metastatic breast cancer (mBC) ( Poster PO1-23-09)
Real-world (RW) utilization and patient outcomes across three CDK4/6 inhibitors in metastatic breast cancer (mBC) (Poster P04-18-02)
The full abstracts are available on the official SABCS 2023 website.